key: cord-0784990-k6qi4zot authors: Dey, S. K.; Rahman, D. M. M.; Siddiqi, D. U. R.; Howlader, A.; Tushar, A. title: Analyzing the Global Impact of COVID-19 Vaccination Progress: A Result-oriented Storytelling Approach date: 2021-03-29 journal: nan DOI: 10.1101/2021.03.26.21254432 sha: ce1df2b076908bb1f8c44f0c45b099902ab3dd4e doc_id: 784990 cord_uid: k6qi4zot The next big step in combating the coronavirus disease 2019 (COVID-19) pandemic will be gaining widespread acceptance of a vaccination campaign for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but achieving high uptake need proper understandings. Many health professionals, researchers, statisticians, and programmers to track the viruses spread in different parts of the world have used various methods. However, the proliferation of vaccines produced by talented scientists around the world has sparked a strong desire to extract meaningful insights from available data. Until now, several vaccines against coronavirus disease (COVID-19) have been approved and are being distributed worldwide in various regions. This study aims to report the detailed data analysis and result-oriented storytelling of the COVID-19 vaccination program of different countries across the globe. To analyze the vaccination trend globally this research utilized two different open datasets provided by ourworldindata.org and worldometers.info. An exploratory data analysis (EDA) with interactive data visualization using various python libraries was conducted, and the results are presented in this article to better understand the impact of ongoing vaccination programs around the world. Apart from the valuable insights gained from the data of various countries, this investigation also included a comparison of the number of confirmed and death cases before and after vaccination to determine the efficacy of each vaccine in each country. The results show that a large number of people are still undecided about whether or not to get a COVID-19 vaccine, despite the virus's continued devastating effects on communities. Overall, our findings contribute to ongoing research aimed at informing policy on how to persuade the unvaccinated to be vaccinated. on, and new, more effective vaccines are likely to emerge as the pandemic progresses [5] [6] . Several vaccines to prevent COVID-19 infection were approved in December 2020, and more than 50 COVID-19 vaccine candidates were being produced [7] [8] . The WHO has identified 48 vaccine candidates that are currently being tested in clinical trials [9] . The first step in developing a vaccine for any virus is to determine its genetic sequence. However, previously, on December 31, 2019, the World Health Organization issued a warning about a new coronavirus strain that is affecting people in China [10] . Later, officials from the China confirmed the identification of a new type of coronavirus infecting human bodies and the first genetic sequence for SARS-CoV-2 was released on January 11, 2020. Non-pharmaceutical interventions are used to minimize transmission and the burden of coronavirus disease 2019 in the absence of safe and highly efficient vaccines and treatment options, but most of these interventions have high economic costs [11] . To reduce the substantial burden of COVID-19 morbidity and mortality, effective COVID-19 vaccines are desperately needed. Vaccine development is a lengthy process that necessitates numerous testing phases to ensure adequate safety and immunogenicity in a variety of people (i.e., different ages, medical conditions, severity of attack, geographic location etc.). According to the National Center for Biotechnology Information (NCBI), a vaccine must go through four stages of clinical trials before receiving a license to produce it, which can take up to a decade. However, due to the urgent pandemic situation around the world, the COVID-19 vaccine development process was shortened to 12-18 months while retaining safety and effectiveness standards. A number of factors, including a monumental breakthrough in biotechnology and molecular biology, as well as a collaboration between government and private research institutes, enables the extreme compression of the COVID-19 vaccine development process. The pandemic's humanitarian and economic consequences are guiding the growth of next-generation vaccine technology platforms around the world. As a result of the COVID-19 vaccine's production being accelerated, the first candidate entered human clinical trials with unparalleled speed on March 16, 2020 [12] . As This section will discuss about the different materials that we employed to build our methods. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 29, 2021. ; One of the important property of EDA before finding the insight form the data is to clean and prepare the data according to the requirements. Therefore, data cleaning is the most important step towards an effective data analysis. In our case, the dataset contains few "NaN" (not a number) values, some empty rows (having value 0), along with some redundant columns. By using and configuring the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.26.21254432 doi: medRxiv preprint function of df.drop from pandas library, we changed "NaN" values to 0 and removed the entire row as per our requirements. This study analyzed the COVID-19 World Vaccination Progress dataset to convey the analysis of different ongoing vaccination programs around the globe. In this section the data analysis results and visualization will be described to find the answers to different query of this research including a) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 29, 2021. ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 is designed based on the map to highlight the countries and their use of different vaccine for their citizens. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To highlight the most and least vaccinated countries and vaccine used we further visualize that data in (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 29, 2021. ; This section will discuss on the findings of this exploration in more border way. Table 4 vaccines including four (4) authorized and seven (7) from clinical phase-III are being used around the world (Table 5 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.26.21254432 doi: medRxiv preprint Based on the results analysis and visualization many countries around the globe started applying vaccine to their citizens by the end of 2020. The rate of applying vaccines to the patients is highest in Isreal. It is because of its small size (in terms of both area and population), a relatively young population, relatively warm weather in December 2020, a centralized national system of government, and well-developed infrastructure for implementing prompt responses to large-scale national emergencies. Until 17 March 2021, The United States has the most vaccinated people of around 110M of its total population followed by China and India. As these are developed countries and they produce vaccine in their own lab; therefore, the accessibility of the vaccine is easier to its public. The impact of using vaccine on specific countries to reduce the spread of COVID-19, we further investigate the confirmed and death cases for the USA, China, UK, India and Brazil after their vaccination campaign starts. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This analysis also emphasized on the different vaccine production and their used in different context. Therefore, following Table 5 is designed to provide an insight about each vaccine that is widely used and popular. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.26.21254432 doi: medRxiv preprint The COVID-19 pandemic is still wreaking havoc on human lives around the world, but the COVID-19 vaccine offers a ray of hope for the future. The global response to the COVID-19 pandemic is likely to rely heavily on vaccine deployment. The present study revealed that globally there is a significant turnaround in people's perception towards vaccination and thus different countries are ensuring mass vaccination for their citizens. The findings also suggests that, rate of vaccination among global population is increasing day by day and as such, unvaccinated peoples around the globe gets more motivated and encouraged to take vaccine in upcoming days. Although vaccines are still unavailable in some parts of the world for various reasons, we believe policymakers should take steps to ensure sufficient knowledge, positive attitudes, and perceptions of COVID-19 vaccinations in order to decrease vaccine hesitancy. All authors conceptualized and designed the study. SKD and MR had the idea for and designed the study and had full access to all the data in the study and take the responsibility for the exploratory data analysis with their visualization. URS and AH and contributed to the writing of the article. MR contributed to the critical revision of the report. All the visualization and data presentation methods developed by SKD, MR, and AT. All authors contributed to data acquisition, data analysis, and reviewed and approved the final version. The data that support the findings of this study are available from the corresponding author, upon reasonable request. The authors declare that there are no conflicts of interest. Not required Not required All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.26.21254432 doi: medRxiv preprint DNA Vaccines: Technology and Application as Anti-parasite and Anti-microbial Agents DNA vaccines for viral infections: Basic studies and applications COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't World Health Organization declares global emergency: A review of the Willingness of future A/H7N9 influenza vaccine uptake: A cross-sectional study of Hong Kong community COVID-19 vaccine research and development: ethical issues CDC, Different COVID-19 Vaccines COVID-19 vaccines Draft landscape and tracker of COVID-19 candidate vaccines The novel coronavirus outbreak in Wuhan, China, Global Health Research and Policy Active case finding with case management: the key to tackling the COVID-19 pandemic The COVID-19 vaccine development landscape Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities COVID-19 vaccine development: What's the progress? | DW | 11 COVID-19 World Vaccination Progress Analyzing the epidemiological outbreak of COVID-19: A visual exploratory data analysis approach